EMA approves label extension for Novartis’ Exjade
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has approved a label extension for Novartis' iron overload treatment Exjade (deferasirox), making the drug available to patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.